$CMPS

Pharmaceutical companies have invested over $5 billion in psychedelic-derived medicines, with Eli Lilly, AbbVie, and Otsuka acquiring firms like AtaiBeckley, Gilgamesh, and Transcend. Compass Pathways' COMP360 is in FDA review for a 2027 launch. The market is projected to reach $11.8B-$14.9B by 2034-2035, driven by high demand for depression treatments. Companies are developing short-acting analogs to reduce clinic stay times.

Investing.com reports COMPASS Pathways (CMPS) trades at $13.45 as of Aug 14, 2026, up 211% over 12 months. The company is pursuing an FDA NDA for COMP360 for treatment-resistant depression, targeting completion in Q4 2026 and review in 2027. It cites Phase 3 results (p<0.001) and $433M cash as of June 30, 2026.

Compass Pathways (CMPS) reported Q2 2026 net loss of $253.8 million, or $1.88 per share, vs $38.4 million, or $0.41 per share, citing noncash warrant fair value adjustments. Cash was $433.3 million at June 30, 2026. The company said COMP360 NDA modules are on track for FDA submission in Q4, with a potential first-half 2027 launch subject to rescheduling.

Investing.com reports Compass Pathways (CMPS) has $433M cash, two Phase 3 positive trials for COMP360, and an NDA expected to be completed in Q4 2026, with a potential H1 2027 FDA approval and launch. Analysts cite a consensus price target of $23.75 versus $13.24. The article highlights key risks including DEA psilocybin rescheduling and possible dilution.

Simply Wall St reports COMPASS Pathways (CMPS) will join the VA PIVOT trial, a multi-site study of its COMP360 therapy in veterans, via a new partnership with the U.S. Department of Veterans Affairs. The article cites CMPS at $13.54, with 7-day return 19.3% and 90-day return 40.31%, plus a shelf registration filing and analyst revenue forecast to $284.9M by July 2029.

Friday’s jobs data showed 23,000 fewer jobs in July and May and June payrolls were revised down by 103,000, easing near-term Fed rate pressure. The 10-year Treasury yield fell to 4.64%. The S&P 500 rose 0.6% to a record as Q2 earnings showed near 50% profit growth. The article also lists options trades in NVO, SPCX, PGEN, OSCR, YOU, PLTR, CF, OUST, CMPS, and ATI.

Compass Pathways (CMPS) shares rose about 16% in pre-market, targeting levels not seen in over two years. The move follows a Trump executive order to speed medical research and treatment access, plus FDA CDER leadership changes. Compass said the FDA granted COMP360 a National Priority Voucher for treatment-resistant depression, and Jefferies estimates 75% to 85% approval odds in FY26.

COMPASS Pathways plc (NASDAQ:CMPS) reported a Q2 2026 basic and diluted loss of $1.88 per share versus a $0.41 consensus estimate, a 358.5% miss, and a net loss of $253.8M. Shares rose 4.9% to $11.80. The company is advancing its psilocybin therapy program in Phase 3 trials, according to the report.

Compass Pathways (CMPS) shares rose about 4.8% after it reported Q2 and first-half 2026 results. The company said it had $433 million cash as of June 30, 2026, enough to fund operations through 2028, and reaffirmed COMP360’s NDA submission in Q4 2026 and U.S. launch in H1 2027, subject to FDA/DEA actions.

Compass Pathways plc (Nasdaq: CMPS) reported Q2 and first-half 2026 results and said its COMP360 psilocybin for treatment-resistant depression showed rapid onset and benefit through at least 6 months in two Phase 3 trials. The company is pursuing a rolling NDA with Q4 completion and expects launch in H1 2027, subject to FDA approval and DEA rescheduling. Cash was $433 million at quarter end.